GlassScriptPhysician profile
Farrah Kang
NPI 1396329215
$1,132.47
in general payments reported to CMS, 2019-2025
22 companies · $726 in 2025
The $726 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $406 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.48 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.86 | 2024-2025 | |
| Eisai INC. | $119.70 | 2025 | |
| Astellas Pharma US INC | $104.38 | 2025 | Veozah |
| Radius Health, INC. | $84.83 | 2024-2025 | Tymlos |
| Lilly USA, LLC | $70.80 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $62.65 | 2024-2025 | |
| Glaxosmithkline, LLC. | $56.29 | 2024-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $53.42 | 2024-2025 | Breztri, Lokelma, Farxiga |
| Lundbeck LLC | $45.75 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $45.58 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $43.20 | 2024-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $37.45 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $32.96 | 2025 | Rexulti |
| Pfizer INC. | $32.60 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $28.95 | 2025 | Alvesco |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $26.39 | 2025 | |
| Abbott Laboratories | $22.50 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $21.11 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $20.36 | 2024 | Aptima, Thinprep 2000 Processor |
| Alnylam Pharmaceuticals INC. | $18.47 | 2024 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $18.29 | 2024 | |
| Corcept Therapeutics | $14.93 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrah Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.